Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 8 | 2026 | 380 | 1.190 |
Why?
|
| Continuity of Patient Care | 4 | 2017 | 174 | 0.670 |
Why?
|
| Patient Participation | 3 | 2020 | 231 | 0.630 |
Why?
|
| Primary Health Care | 4 | 2024 | 717 | 0.570 |
Why?
|
| Patient Readmission | 3 | 2015 | 444 | 0.480 |
Why?
|
| Office Visits | 2 | 2014 | 48 | 0.440 |
Why?
|
| Patient Discharge | 6 | 2017 | 518 | 0.420 |
Why?
|
| Reminder Systems | 3 | 2020 | 75 | 0.410 |
Why?
|
| Ambulatory Care | 2 | 2014 | 316 | 0.390 |
Why?
|
| Text Messaging | 3 | 2020 | 95 | 0.320 |
Why?
|
| Patient Care | 2 | 2020 | 77 | 0.290 |
Why?
|
| Patient Portals | 2 | 2020 | 52 | 0.280 |
Why?
|
| Health Information Interoperability | 2 | 2018 | 4 | 0.280 |
Why?
|
| Aged | 21 | 2025 | 14834 | 0.250 |
Why?
|
| Vaccination | 2 | 2020 | 374 | 0.250 |
Why?
|
| Smoking Cessation | 2 | 2022 | 552 | 0.230 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2013 | 142 | 0.230 |
Why?
|
| Medication Errors | 3 | 2021 | 110 | 0.220 |
Why?
|
| Aged, 80 and over | 12 | 2022 | 5562 | 0.220 |
Why?
|
| Autoimmune Diseases | 1 | 2025 | 239 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 797 | 0.200 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2023 | 22 | 0.200 |
Why?
|
| Multiple Sclerosis | 1 | 2026 | 226 | 0.200 |
Why?
|
| Male | 21 | 2026 | 30790 | 0.190 |
Why?
|
| Mobile Applications | 2 | 2024 | 140 | 0.180 |
Why?
|
| Hypertension | 2 | 2020 | 609 | 0.180 |
Why?
|
| Female | 21 | 2026 | 33739 | 0.180 |
Why?
|
| Humans | 30 | 2026 | 64729 | 0.180 |
Why?
|
| Medication Systems | 1 | 2021 | 17 | 0.170 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 427 | 0.170 |
Why?
|
| Influenza, Human | 2 | 2020 | 203 | 0.160 |
Why?
|
| Massachusetts | 4 | 2025 | 2137 | 0.160 |
Why?
|
| Drug Monitoring | 3 | 2011 | 202 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 63 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 140 | 0.160 |
Why?
|
| Communication | 1 | 2024 | 593 | 0.150 |
Why?
|
| Pharmacists | 1 | 2021 | 130 | 0.150 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 78 | 0.150 |
Why?
|
| Middle Aged | 12 | 2026 | 18106 | 0.150 |
Why?
|
| Health Planning Guidelines | 1 | 2018 | 31 | 0.140 |
Why?
|
| Comorbidity | 4 | 2025 | 1115 | 0.140 |
Why?
|
| Population Health | 1 | 2018 | 17 | 0.140 |
Why?
|
| Patient Selection | 1 | 2020 | 483 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 491 | 0.130 |
Why?
|
| Motivation | 1 | 2020 | 295 | 0.130 |
Why?
|
| Accidental Falls | 1 | 2018 | 129 | 0.130 |
Why?
|
| Consensus | 1 | 2018 | 181 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 98 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 727 | 0.120 |
Why?
|
| Transitional Care | 1 | 2015 | 32 | 0.120 |
Why?
|
| Social Determinants of Health | 1 | 2018 | 148 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 255 | 0.110 |
Why?
|
| Medical Informatics | 1 | 2015 | 72 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 80 | 0.110 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 12 | 0.100 |
Why?
|
| Meaningful Use | 1 | 2013 | 9 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1211 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2013 | 62 | 0.100 |
Why?
|
| Health Records, Personal | 1 | 2013 | 26 | 0.100 |
Why?
|
| Metformin | 1 | 2014 | 75 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2013 | 106 | 0.090 |
Why?
|
| Adult | 7 | 2026 | 17230 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 484 | 0.090 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2012 | 7 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2025 | 6803 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 2 | 2010 | 105 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 225 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 2 | 2010 | 120 | 0.090 |
Why?
|
| Weight Loss | 1 | 2013 | 274 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 343 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 158 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 252 | 0.070 |
Why?
|
| Safety Management | 1 | 2010 | 136 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 155 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2483 | 0.070 |
Why?
|
| Telemedicine | 1 | 2013 | 357 | 0.070 |
Why?
|
| Young Adult | 3 | 2026 | 4771 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2004 | 48 | 0.060 |
Why?
|
| Hospitalization | 3 | 2021 | 1384 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 178 | 0.060 |
Why?
|
| Demography | 1 | 2026 | 178 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2024 | 260 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 3745 | 0.050 |
Why?
|
| Group Practice | 1 | 2003 | 11 | 0.050 |
Why?
|
| Incidence | 3 | 2014 | 1409 | 0.050 |
Why?
|
| United States | 4 | 2026 | 8041 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2003 | 56 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1555 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 84 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 63 | 0.040 |
Why?
|
| Technology | 1 | 2022 | 53 | 0.040 |
Why?
|
| Prevalence | 1 | 2026 | 1432 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1135 | 0.040 |
Why?
|
| New England | 3 | 2010 | 269 | 0.040 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 3 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 22 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2023 | 494 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 37 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 142 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 1001 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 290 | 0.040 |
Why?
|
| Reward | 1 | 2020 | 89 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 2086 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 95 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 325 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 318 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 16 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 461 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 37 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 6291 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 278 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2018 | 49 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 433 | 0.030 |
Why?
|
| California | 1 | 2018 | 173 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 669 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 122 | 0.030 |
Why?
|
| Community Health Services | 1 | 2018 | 124 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 583 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 695 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 872 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 1580 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 5393 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 238 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 188 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 160 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 75 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 104 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2013 | 20 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2013 | 39 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2013 | 2603 | 0.020 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 68 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 734 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2014 | 121 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 929 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 247 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 381 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 525 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 796 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2011 | 49 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 822 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2012 | 113 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 414 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 885 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 859 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 35 | 0.010 |
Why?
|
| Diuretics | 1 | 2004 | 58 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2680 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 139 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2004 | 103 | 0.010 |
Why?
|
| Medicare Part B | 1 | 2003 | 11 | 0.010 |
Why?
|
| Medicare Part C | 1 | 2003 | 14 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 987 | 0.010 |
Why?
|
| Medicare | 1 | 2004 | 615 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 520 | 0.010 |
Why?
|